Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.

Ruiz-de-Angulo A, Zabaleta A, Gómez-Vallejo V, Llop J, Mareque-Rivas JC.

ACS Nano. 2016 Jan 26;10(1):1602-18. doi: 10.1021/acsnano.5b07253. Epub 2016 Jan 5.

PMID:
26678549
2.

Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.

Zabaleta A, Riezu-Boj JI, Larrea E, Villanueva L, Lasarte JJ, Guruceaga E, Fisicaro P, Ezzikouri S, Missale G, Ferrari C, Benjelloun S, Prieto J, Sarobe P.

J Med Virol. 2016 May;88(5):843-51. doi: 10.1002/jmv.24399. Epub 2015 Oct 19.

PMID:
26447929
3.

[Tuberculosis and drug-resistance tuberculosis in prisoners. Colombia, 2010-2012].

Gómez IT, Llerena CR, Zabaleta AP.

Rev Salud Publica (Bogota). 2015 Jan-Feb;17(1):97-105. Spanish.

4.

Drafting the proteome landscape of myeloid-derived suppressor cells.

Gato M, Blanco-Luquin I, Zudaire M, de Morentin XM, Perez-Valderrama E, Zabaleta A, Kochan G, Escors D, Fernandez-Irigoyen J, Santamaría E.

Proteomics. 2016 Jan;16(2):367-78. doi: 10.1002/pmic.201500229. Epub 2015 Dec 14. Review.

PMID:
26403437
5.

[Evaluation of the BD MGITTM technique for identifying the Mycobacterium tuberculosis complex].

Gómez IT, Llerena CR, Zabaleta AP.

Rev Salud Publica (Bogota). 2014 Sep-Oct;16(5):765-71. Spanish.

6.

Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.

Zabaleta A, D'Avola D, Echeverria I, Llopiz D, Silva L, Villanueva L, Riezu-Boj JI, Larrea E, Pereboev A, Lasarte JJ, Rodriguez-Lago I, Iñarrairaegui M, Sangro B, Prieto J, Sarobe P.

Mol Ther Methods Clin Dev. 2015 Mar 11;2:15006. doi: 10.1038/mtm.2015.6. eCollection 2015.

7.

An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.

Hernández-Gil J, Cobaleda-Siles M, Zabaleta A, Salassa L, Calvo J, Mareque-Rivas JC.

Adv Healthc Mater. 2015 May;4(7):1034-42. doi: 10.1002/adhm.201500080. Epub 2015 Apr 2.

PMID:
25846677
8.

Simulation climate change impact on runoff and sediment yield in a small watershed in the basque country, northern Spain.

Zabaleta A, Meaurio M, Ruiz E, Antigüedad I.

J Environ Qual. 2014 Jan;43(1):235-45. doi: 10.2134/jeq2012.0209.

PMID:
25602556
9.

Toward defining the anatomo-proteomic puzzle of the human brain: An integrative analysis.

Fernandez-Irigoyen J, Labarga A, Zabaleta A, de Morentin XM, Perez-Valderrama E, Zelaya MV, Santamaria E.

Proteomics Clin Appl. 2015 Oct;9(9-10):796-807. doi: 10.1002/prca.201400127. Epub 2015 Feb 24. Review.

PMID:
25418211
10.

Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.

Llopiz D, Huarte E, Ruiz M, Bezunartea J, Belsúe V, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Oncoimmunology. 2013 Dec 1;2(12):e27009. Epub 2013 Dec 5.

11.

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.

Echeverria I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, Bes M, Cubero M, Borras-Cuesta F, Lasarte JJ, Esteban JI, Prieto J, Sarobe P.

Hepatology. 2011 Jul;54(1):28-37. doi: 10.1002/hep.24325. Epub 2011 May 14.

PMID:
21452282
12.

Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C).

Echeverría I, Zabaleta A, Silva L, Díaz-Valdés N, Riezu-Boj JI, Lasarte JJ, Borrás-Cuesta F, Civeira MP, Prieto J, Sarobe P.

J Viral Hepat. 2008 Nov;15(11):782-9. doi: 10.1111/j.1365-2893.2008.01020.x. Epub 2008 Jul 10.

PMID:
18637068
13.

Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.

Zabaleta A, Llopiz D, Arribillaga L, Silva L, Riezu-Boj JI, Lasarte JJ, Borrás-Cuesta F, Prieto J, Sarobe P.

Mol Ther. 2008 Jan;16(1):210-7. Epub 2007 Oct 9.

PMID:
17923840
14.

Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.

Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Cancer Immunol Immunother. 2008 Jan;57(1):19-29. Epub 2007 Jun 13.

PMID:
17564702
15.

Structured group-based education for type 2 diabetes in primary care.

Zabaleta AM, Forbes A.

Br J Community Nurs. 2007 Apr;12(4):158-62. Review.

PMID:
17505331
16.

[Health related quality of life in patients with diabetes mellitus type 2].

Hervás A, Zabaleta A, De Miguel G, Beldarráin O, Díez J.

An Sist Sanit Navar. 2007 Jan-Apr;30(1):45-52. Spanish.

17.

Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.

Zabaleta A, Arribillaga L, Llopiz D, Dotor J, Lasarte JJ, Prieto J, Borrás-Cuesta F, Esteban JI, Quer J, Vayreda F, Sarobe P.

Antiviral Res. 2007 Apr;74(1):25-35. Epub 2007 Jan 22.

PMID:
17275104
18.

Engineered promiscuous T helper peptides for the induction of immune responses.

Ruiz M, Llopiz D, Zabaleta A, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Mol Immunol. 2007 Mar;44(9):2205-12. Epub 2006 Dec 8.

PMID:
17157914
19.

[Impact of common reasons for consultation on the feeling of vitality and the physical performance of the over-65s].

Sánchez Lasheras T, Goñi Ruiz N, Serrano-Martínez M, Buil P, Zabaleta A, de Miguel G, Beldarrain O, Díez Espino J.

Aten Primaria. 2005 Mar 31;35(5):246-52. Spanish.

20.

Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.

Stefansson S, Yepes M, Gorlatova N, Day DE, Moore EG, Zabaleta A, McMahon GA, Lawrence DA.

J Biol Chem. 2004 Jul 16;279(29):29981-7. Epub 2004 May 6.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk